72 related articles for article (PubMed ID: 21890007)
21. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
22. Toxin A-negative, toxin B-positive Clostridium difficile.
Drudy D; Fanning S; Kyne L
Int J Infect Dis; 2007 Jan; 11(1):5-10. PubMed ID: 16857405
[TBL] [Abstract][Full Text] [Related]
23. Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864--implications for transcription, expression and enzymatic activity of toxins A and B.
Soehn F; Wagenknecht-Wiesner A; Leukel P; Kohl M; Weidmann M; von Eichel-Streiber C; Braun V
Mol Gen Genet; 1998 May; 258(3):222-32. PubMed ID: 9645428
[TBL] [Abstract][Full Text] [Related]
24. Release of TcdA and TcdB from Clostridium difficile cdi 630 is not affected by functional inactivation of the tcdE gene.
Olling A; Seehase S; Minton NP; Tatge H; Schröter S; Kohlscheen S; Pich A; Just I; Gerhard R
Microb Pathog; 2012 Jan; 52(1):92-100. PubMed ID: 22107906
[TBL] [Abstract][Full Text] [Related]
25. Emerging toxin A-B+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea.
Shin BM; Kuak EY; Yoo SJ; Shin WC; Yoo HM
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):333-7. PubMed ID: 18082994
[TBL] [Abstract][Full Text] [Related]
26. Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects.
Teichert M; Tatge H; Schoentaube J; Just I; Gerhard R
Infect Immun; 2006 Oct; 74(10):6006-10. PubMed ID: 16988280
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B.
Gerhard R; Queisser S; Tatge H; Meyer G; Dittrich-Breiholz O; Kracht M; Feng H; Just I
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):285-95. PubMed ID: 21267712
[TBL] [Abstract][Full Text] [Related]
28. Retracted: Apoptosis of CT26 colorectal cancer cells induced by Clostridium difficile toxin A stimulates potent anti-tumor immunity.
Tian Y; Huang T; Li G; Liu J; Wang X; Feng H; Wang J
Biochem Biophys Res Commun; 2012 May; 422(1):15-21. PubMed ID: 22548800
[TBL] [Abstract][Full Text] [Related]
29. Toxin A of the nosocomial pathogen Clostridium difficile induces primary effects in the proteome of HEp-2 cells.
Junemann J; Birgin G; Erdmann J; Schröder A; Just I; Gerhard R; Pich A
Proteomics Clin Appl; 2017 Mar; 11(3-4):. PubMed ID: 27860399
[TBL] [Abstract][Full Text] [Related]
30. Structure of the glucosyltransferase domain of TcdA in complex with RhoA provides insights into substrate recognition.
Chen B; Liu Z; Perry K; Jin R
Sci Rep; 2022 May; 12(1):9028. PubMed ID: 35637242
[TBL] [Abstract][Full Text] [Related]
31. Clostridium difficile toxins: mechanism of action and role in disease.
Voth DE; Ballard JD
Clin Microbiol Rev; 2005 Apr; 18(2):247-63. PubMed ID: 15831824
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.
Zhang Y; Feng H
Pathog Dis; 2016 Jun; 74(4):ftw024. PubMed ID: 27044305
[TBL] [Abstract][Full Text] [Related]
33. Glucosyltransferase-dependent and -independent effects of TcdB on the proteome of HEp-2 cells.
Erdmann J; Junemann J; Schröder A; Just I; Gerhard R; Pich A
Proteomics; 2017 Aug; 17(15-16):. PubMed ID: 28612519
[TBL] [Abstract][Full Text] [Related]
34. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
[TBL] [Abstract][Full Text] [Related]
35.
Schweitzer T; Genth H; Pich A
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077344
[No Abstract] [Full Text] [Related]
36. [Laboratory-based evaluation of TOX A/B QUIK CHEK "NISSUI" to detect toxins A and B of clostridium difficile].
Nakasone I; Shiohira CM; Yamane N
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2007; 18(2):109-16. PubMed ID: 18154439
[TBL] [Abstract][Full Text] [Related]
37. Binding of Clostridium difficile toxins to human milk oligosaccharides.
El-Hawiet A; Kitova EN; Kitov PI; Eugenio L; Ng KK; Mulvey GL; Dingle TC; Szpacenko A; Armstrong GD; Klassen JS
Glycobiology; 2011 Sep; 21(9):1217-27. PubMed ID: 21610194
[TBL] [Abstract][Full Text] [Related]
38. Comparison of VIDAS CDAB and CDA immunoassay for the detection of Clostridium difficile in a tcdA- tcdB+ C. difficile prevalent area.
Shin BM; Lee EJ; Kuak EY; Yoo SJ
Anaerobe; 2009 Dec; 15(6):266-9. PubMed ID: 19772927
[TBL] [Abstract][Full Text] [Related]
39. Pyknotic cell death induced by Clostridium difficile TcdB: chromatin condensation and nuclear blister are induced independently of the glucosyltransferase activity.
Wohlan K; Goy S; Olling A; Srivaratharajan S; Tatge H; Genth H; Gerhard R
Cell Microbiol; 2014 Nov; 16(11):1678-92. PubMed ID: 24898616
[TBL] [Abstract][Full Text] [Related]
40. Protection from Clostridium difficile toxin B-catalysed Rac1/Cdc42 glucosylation by tauroursodeoxycholic acid-induced Rac1/Cdc42 phosphorylation.
Brandes V; Schelle I; Brinkmann S; Schulz F; Schwarz J; Gerhard R; Genth H
Biol Chem; 2012 Jan; 393(1-2):77-84. PubMed ID: 22628301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
